Skip to main content

Table 2 Drug-induced adverse events according to the common terminology criteria for adverse events version 3.0 or 4.0

From: Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma

 

All grades

Grade 3 or 4

No. (%)

No. (%)

Adverse events

181 (94.8)

103 (53.9)

Hand-foot skin reaction

120 (62.8)

38 (19.9)

Elevated AST

114 (59.7)

26 (13.6)

Elevated ALT

103 (53.9)

14 (7.3)

Fatigue

98 (51.3)

13 (6.8)

Appetite loss

84 (44.0)

20 (10.5)

Diarrhea

76 (39.8)

12 (6.3)

Hypertension

73 (38.2)

11 (5.8)

Skin rash

40 (20.9)

5 (2.6)

Voice changes

23 (12.0)

2 (1.0)

Alopecia

23 (12.0)

0 (0.0)

Gastrointestinal bleeding

4 (2.1)

1 (0.5)

Variceal bleeding

3 (1.6)

2 (1.0)

  1. ALT alanine aminotransferase, AST aspartate aminotransferase